113
Participants
Start Date
October 18, 2021
Primary Completion Date
July 5, 2023
Study Completion Date
July 24, 2023
AND017
Orally, 3 times per week in Period 1 and randomize to TIW or QW group at the same dose in Period 2
Placebo
Orally, 3 times per week
Metrolina Nephrology Associates, Charlotte
Clinical Site Partners, Winter Park
Southeast Renal Research Institute, Chattanooga
Elite Research Center, Flint
Northwest Louisiana Nephrology, Shreveport
Clinical Advancement Center, PLLC, San Antonio
Amicis Research Center, Northridge
Peking University People's Hospital, Beijing
Lead Sponsor
Kind Pharmaceuticals LLC
INDUSTRY